Subgenomic SARS-CoV-2 replicon and reporter replicon cell lines enable ultrahigh throughput antiviral screening and mechanistic studies with antivirals, viral mutations or host factors that affect COVID-19 replication
Lan, S.; Tedbury, P. R.; Ong, Y. T.; Shah, R.; Slack, R. L.; Cilento, M. E.; Zhang, H.; Du, H.; Lulkin, N.; Le, U. Q.; Kirby, K. A.; Melcak, I.; Cantara, W. A.; Boggs, E. A.; Sarafianos, S. G.
Show abstract
Replicon-based technologies were used to develop reagents and assays for advanced drug discovery efforts against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and for examining all facets of the SARS-CoV-2 replication cycle at reduced biocontainment level. Specifically: a) 21 replicons were cloned in bacterial artificial chromosomes (BACs) and delivered as transfectable plasmid DNA or transcribed RNA in various cell types. Replicons carrying mutations that affect the activity or antiviral susceptibility of SARS-CoV-2 enzymes were used to establish utility for mechanistic studies while reducing the community risks associated with gain-of-function studies in fully infectious virus. b) A BHK-21 stable cell line harboring SARS-CoV-2 replicon was generated and characterized in robust high/ultra-high throughput assays of antiviral efficacy with orthogonal SARS-CoV-2 replication reporter genes (Nano luciferase and enhanced green fluorescent protein-eGFP); the estimated antiviral potencies in the fully infectious SARS-CoV-2 system and in the transient or stable replicon systems were similar. HEK293 and Calu1 stable cell lines expressing SARS-CoV-2 replicon have also been prepared. Finally, c) we generated trans-encapsidated replicons by co-expression with SARS-CoV-2 structural proteins, thus producing single-round infectious SARS-CoV-2 virus-like particles that are able to transduce susceptible cell types and have expanded utility to enable study of virion assembly and entry into target cells. Hence, these SARS-CoV-2 replicon-based reagents include a novel approach to replicon-harboring cell line generation and are valuable tools that can be used at lower biosafety level (BSL2) for drug discovery efforts, characterization of SARS-CoV-2 and variant evolution in the COVID-19 pandemic, mechanisms of inhibition and resistance, and studies on the role of SARS-CoV-2 genes and host dependency factors.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen 97%
- Generation and Characterization of recombinant SARS-CoV-2 expressing reporter genes 97%
- The enzymatic activity of the nsp14 exoribonuclease is critical for replication of Middle East respiratory syndrome-coronavirus 97%
Similar papers in this journal
- The RNA pseudoknots in foot-and-mouth disease virus are dispensable for genome replication but essential for the production of infectious virus. 97%
- Human coronaviruses disassemble processing bodies 96%
- Thiopurines inhibit coronavirus Spike protein processing and incorporation into progeny virions 96%
Similar papers in this journal
- Development of SARS-CoV-2 replicons for the ancestral virus and variant of concern Delta for antiviral screening. 98%
- Analysis of factors that regulate HIV-1 fusion in reverse 96%
- Doxycycline inhibition of a pseudotyped virus transduction does not translate to inhibition of SARS-CoV-2 infectivity 96%
Similar papers in this journal
- SARS-CoV-2 Permissive Glioblastoma Cell Line for High Throughput Antiviral Screening 97%
- The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses 96%
- Development and optimization of a novel T7 polymerase-independent Marburg virus minigenome system 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.